Aandeel 7325 IRRC CORPORATION
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen IRRC Corporation

Aandelen

7325

JP3105230001

Beurs gesloten - Japan Exchange
Andere beurzen
 08:00:00 26-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
730 JPY -0,41% Intraday-grafiek van IRRC Corporation +1,11% +13,00%
2023 IRRC Corporation (TSE:7325) voltooide de overname van 80,9% belang in Life Assist Co., Ltd. van Orix Life Insurance Corporation. CI
2023 IRRC Corporation (TSE:7325) kondigt een aandeleninkoop aan voor 200.000 aandelen, die 2,38% vertegenwoordigen voor ¥160 miljoen. CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
IRRC Corporation's Equity Buyback announced on August 18, 2023, has closed with 200,000 shares, representing 2.39% for ¥140.90 million.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
Henlius Biotech, Inc. - Results from Four Phase 1/2 Clinical Trials of Henlius Innovative Products Released at 2023 ESMO Asia
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
IRRC Corporation completed the acquisition of 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation.
IRRC Corporation announces an Equity Buyback for 200,000 shares, for ¥160 million.
IRRC Corporation authorizes a Buyback Plan.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
IRRC Corporation's Equity Buyback announced on February 14, 2023, has closed with 300,300 shares, representing 3.48% for ¥228.63 million.
IRRC Corporation signed a basic agreement to acquire a 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation for approximately ¥400 million.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
IRRC Corporation Reports Earnings Results for the Nine Months Ended March 31, 2023
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
CStone Announces Publication of GEMSTONE-201 Study Results for Sugemalimab Monotherapy in the Treatment of Relapsed, Refractory Extranodal NK/T-Cell Lymphoma in Journal of Clinical Oncology
IRRC Corporation announces an Equity Buyback for 500,000 shares, representing 5.74% for ¥400 million.
IRRC Corporation authorizes a Buyback Plan.
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022
IRRC : Pennsylvania Takes Next Step Toward Cap-and-Trade Amid Resistance
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 7325
  4. Nieuws IRRC Corporation
  5. Andere talen